Evidence map›Paper›PMID 42418504›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Lecanemab treatment improves B cell subpopulation immune homeostasis in patients with Alzheimer's disease.

Yutong Cai, Yuxuan Wang, Wenjing Huang, Ying Su, Ming Lei, Ruonan Jia, Chenyue Wu, Tianming Zhang, Lanlan Sun, Bihao Peng and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yutong CaiDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Yuxuan WangBeijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, Beihang University, Beijing, China.
Wenjing HuangThe School of Public Health, Fujian Medical University, Fuzhou, China.
Ying SuDepartment of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ming LeiDepartment of Neurology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
Ruonan JiaBeijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, Beihang University, Beijing, China.
Chenyue WuBeijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, Beihang University, Beijing, China.
Tianming ZhangBeijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, Beihang University, Beijing, China.
Lanlan SunBeijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, Beihang University, Beijing, China.
Bihao PengDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Jun ChengCollege of Mechanical and Electrical Engineering, Fujian Agriculture and Forestry University, Fuzhou, China.
Jintai YuDepartment of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and Ministry of Education Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China.
Xiaochun ChenDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.ORCID https://orcid.org/0000-0002-2665-4155
Qinyong YeDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Jian YuBeijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, Beihang University, Beijing, China.
Jiawei XinDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.

Funding

Brain Science and Brain-like Intelligence Technology-National Science and Technology Major Project 2022ZD0211603Lingang Laboratory ADB510200National Natural Science Foundation of China 82371188National Natural Science Foundation of China 82571602
6 · The paper itself

Abstract

introductionLecanemab, the first disease-modifying therapy for Alzheimer's disease (AD), mitigates pathology primarily by clearing amyloid plaques, but its impact on peripheral immunity remains unclear.

methodsTo assess Lecanemab's immunological effects, we performed antibody array analysis of serum and single-cell RNA sequencing of peripheral blood mononuclear cells collected from healthy controls and patients with AD at baseline, 3, and 6 months post-treatment.

resultsLecanemab restored multiple serum chemokines to healthy levels in patients with AD. Compared to controls, baseline samples from patients with AD showed altered frequencies and functions of naïve and unswitched memory (UswM) B cells. Lecanemab treatment corrected the abnormal naïve and UswM B cell proportions and rebuilt their functional homeostasis by alleviating chronic inflammation and reversing the dysregulation of key pathways including immune response, NF-κB, RAGE, and cell adhesion. DISCUSSION: These findings uncover a novel peripheral immunomodulatory mechanism of Lecanemab, offering new insights into AD therapeutics.

Indexed as

Alzheimer DiseaseAntibodies, MonoclonalB-LymphocytesB-Lymphocyte SubsetsHomeostasisAgedFemaleHumansLeukocytes, MononuclearMaleAntibodies, MonoclonalAlzheimer's diseaseB cellsLecanemabperipheral immunitysingle‐cell RNA sequencing

Identifiers

PMID42418504
PMCPMC13344887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.